SOURCE: Actinium Pharmaceuticals

Actinium Pharmaceuticals

May 10, 2016 07:00 ET

Actinium to Present at BIO International Convention and Provide Updates on Actimab-A and Iomab-B Programs

Company to Actively Participate in Partnering Meetings as Clinical Development of Key Programs Advances

NEW YORK, NY--(Marketwired - May 10, 2016) -  Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or the "Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that members of the Company's management team will be attending the 2016 BIO International Convention being held June 6 - 9, 2016 in San Francisco, California. Actinium's management will highlight recent updates related to Actimab-A and Iomab-B during one-on-one partnering activities and will provide a corporate update in its formal company presentation, that is part of the BIO International Convention program.

Actimab-A is in a multi-center Phase 1/2 clinical trial for patients with newly diagnosed Acute Myeloid Leukemia (AML) over the age of 60. Actinium expects to be in a position to discuss the completed results of the Phase 1 portion of the Actimab-A clinical trial in addition to putting these results into the context of results from prior trials conducted as part of their HuM195-alpha program. Iomab-B is poised to begin the pivotal Phase 3 SIERRA trial for patients with relapsed or refractory AML over the age of 55 in preparation for a bone marrow transplant in mid-2016.

Members of Actinium's management team will be available for one-on-one meetings with conference attendees. To arrange a meeting with management, please contact David Gould, Actinium's Senior Vice President, Corporate Development and Corporate Affairs at dgould@actiniumpharma.com or request them through the BIO One-on-One Partnering™ system http://convention.bio.org/partner/.

Sandesh Seth, Actinium's Executive Chairman said, "BIO International brings several thousand biopharmaceuticals companies together under one roof making for a very exciting convention. With Iomab-B and Actimab-A poised to move into Phase 3 and Phase 2 trials, respectively, and the updated information we expect to have on our Actimab-A program, we are very excited to attend this year's BIO event."

About Actimab-A

Actimab-A, Actinium's most advanced alpha particle immunotherapy program is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single arm multicenter trial. Actimab-A is being developed as a first line therapy and has attracted support from some of the leading experts at the most prestigious cancer treatment hospitals due to the potential of its safety and efficacy profile. Actimab-A consists of the Lintuzumab monoclonal antibody and actinium-225. Actinium-225 decays by giving off high-energy alpha particles, which kill cancer cells. When actinium decays, it produces a series of daughter atoms, each of which gives off its own alpha particle, increasing the chances that the cancer cell will be destroyed. Lintuzumab is the humanized version of M195 and is a monoclonal antibody that targets CD33, found on myeloid leukemia cells. Both the alpha particle technology and Lintuzumab were initially developed at Memorial Sloan Kettering Cancer Center.

About Iomab-B

Iomab-B is a radioimmunoconjugate consisting of BC8, a novel murine monoclonal antibody, and iodine-131 radioisotope. BC8 has been developed by the Fred Hutchinson Cancer Research Center to target CD45, a pan-leukocytic antigen widely expressed on white blood cells. This antigen makes BC8 potentially useful in targeting white blood cells in preparation for a hematopoietic stem cell transplantation, referred to as a bone marrow transplant, in a number of blood cancer indications, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin's disease (HD), Non-Hodgkin lymphomas (NHL) and multiple myeloma (MM). When labeled with radioactive isotopes, BC8 carries radioactivity directly to the site of cancerous growth and bone marrow while avoiding effects of radiation on most healthy tissues.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. (www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical product candidate Iomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company plans to conduct a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory and relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second product candidate, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.

Forward-Looking Statements for Actinium Pharmaceuticals, Inc.

This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Contact Information